Literature DB >> 16696571

Bioactivation of carboxylic acid compounds by UDP-Glucuronosyltransferases to DNA-damaging intermediates: role of glycoxidation and oxidative stress in genotoxicity.

Benedetta C Sallustio1, Yvette C Degraaf, Josephine S Weekley, Philip C Burcham.   

Abstract

Nonenzymatic modification of proteins by acyl glucuronides is well documented; however, little is known about their potential to damage DNA. We have previously reported that clofibric acid undergoes glucuronidation-dependent bioactivation to DNA-damaging species in cultured mouse hepatocytes. The aim of this study was to investigate the mechanisms underlying such DNA damage, and to screen chemically diverse carboxylic acid drugs for their DNA-damaging potential in glucuronidation proficient murine hepatocytes. Cells were incubated with each aglycone for 18 h, followed by assessment of compound cytotoxicity using the MTT assay and evaluation of DNA damage using the Comet assay. Relative cytotoxic potencies were ketoprofen > diclofenac, benoxaprofen, nafenopin >> gemfibrozil, probenecid > bezafibrate > clofibric acid. At a noncytotoxic (0.1 mM) concentration, only benoxaprofen, nafenopin, clofibric acid, and probenecid significantly increased Comet moments (P < 0.05 Kruskal-Wallis). Clofibric acid and probenecid exhibited the greatest DNA-damaging potency, producing significant DNA damage at 0.01 mM concentrations. The two drugs produced maximal increases in Comet moment of 4.51 x and 2.57 x control, respectively. The glucuronidation inhibitor borneol (1 mM) abolished the induction of DNA damage by 0.5 mM concentrations of clofibric acid and probenecid. In an in vitro cell-free system, clofibric acid glucuronide was 10 x more potent than glucuronic acid in causing DNA strand-nicking, although both compounds showed similar rates of autoxidation to generate hydroxyl radicals. In cultured hepatocytes, the glycation inhibitor, aminoguanidine, and the iron chelator, desferrioxamine mesylate, inhibited DNA damage by clofibric acid, whereas the free radical scavengers Trolox and butylated hydroxytoluene, and the superoxide dismutase mimetic bis-3,5-diisopropylsalicylate had no effect. In conclusion, clinically relevant concentrations of two structurally unrelated carboxylic acids, probenecid and clofibric acid, induced DNA damage in isolated hepatocytes via glucuronidation- dependent pathways. These findings suggest acyl glucuronides are able to access and damage nuclear DNA via iron-catalyzed glycation/glycoxidative processes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16696571     DOI: 10.1021/tx060022k

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  4 in total

1.  Evidence of glucuronidation of the glycation product LW-1: tentative structure and implications for the long-term complications of diabetes.

Authors:  David R Sell; Ina Nemet; Zhili Liang; Vincent M Monnier
Journal:  Glycoconj J       Date:  2018-01-05       Impact factor: 2.916

2.  Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use.

Authors:  Monika Pawlowska; Rong Chu; Barbara Fedejko-Kap; Ewa Augustin; Zofia Mazerska; Anna Radominska-Pandya; Timothy C Chambers
Journal:  Drug Metab Dispos       Date:  2012-11-16       Impact factor: 3.922

3.  Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10.

Authors:  Barbara Fedejko-Kap; Stacie M Bratton; Moshe Finel; Anna Radominska-Pandya; Zofia Mazerska
Journal:  Drug Metab Dispos       Date:  2012-06-01       Impact factor: 3.922

4.  The expression of Phase II drug-metabolizing enzymes in human B-lymphoblastoid TK6 cells.

Authors:  Xilin Li; Yuxi Li; Kylie G Ning; Si Chen; Lei Guo; Jessica A Bonzo; Nan Mei
Journal:  J Environ Sci Health C Toxicol Carcinog       Date:  2022-03-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.